Krystal Biotech Inc (NASDAQ:KRYS) – Investment analysts at William Blair dropped their Q1 2019 earnings estimates for shares of Krystal Biotech in a research note issued to investors on Wednesday, March 13th. William Blair analyst R. Prasad now anticipates that the company will post earnings per share of ($0.39) for the quarter, down from their previous forecast of ($0.35). William Blair also issued estimates for Krystal Biotech’s Q2 2019 earnings at ($0.41) EPS, Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.69) EPS and FY2020 earnings at ($2.10) EPS.

Several other equities analysts have also commented on the stock. Zacks Investment Research lowered shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday. Chardan Capital raised their price target on shares of Krystal Biotech from $50.00 to $57.50 and gave the stock a “buy” rating in a report on Tuesday, March 12th. ValuEngine raised shares of Krystal Biotech from a “buy” rating to a “strong-buy” rating in a report on Friday, March 1st. HC Wainwright reissued a “buy” rating and issued a $32.00 price target on shares of Krystal Biotech in a report on Tuesday, January 15th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $34.00 price target on shares of Krystal Biotech in a report on Wednesday, December 19th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $36.90.

KRYS stock opened at $21.10 on Friday. Krystal Biotech has a 52 week low of $8.91 and a 52 week high of $28.75. The firm has a market cap of $304.49 million, a P/E ratio of -21.75 and a beta of 0.55.

A number of institutional investors have recently made changes to their positions in the business. Knott David M purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $31,000. New York State Common Retirement Fund purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $159,000. BlackRock Inc. lifted its position in shares of Krystal Biotech by 75.4% in the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares during the period. Citigroup Inc. purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $214,000. Finally, BB&T Securities LLC purchased a new stake in shares of Krystal Biotech in the 4th quarter worth about $228,000. 43.04% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Earnings History and Estimates for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.